By: Ramos

H.B. No. 1710

	A BILL TO BE ENTITLED
1	AN ACT
2	relating to discussing with a patient the risks of certain
3	controlled substance prescriptions.
4	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
5	SECTION 1. Section 481.0764, Health and Safety Code, is
6	amended by adding Subsections (f) and (g) to read as follows:
7	(f) A prescriber, other than a veterinarian, on issuance of
8	the initial prescription for a Schedule II controlled substance or
9	an opioid, shall discuss with the patient and, if the patient is a
10	minor, the patient's parent, conservator, or guardian, or other
11	person authorized to consent to the minor's medical treatment:
12	(1) the risk of addiction associated with the drug
13	prescribed, including any risk of developing a physical or
14	psychological dependence on the drug;
15	(2) the risk of overdose associated with the drug
16	prescribed; and
17	(3) the danger of taking the drug with
18	benzodiazepines, alcohol, or other central nervous system
19	depressants.
20	(g) A prescriber who discusses the risks of a controlled
21	substance prescription under Subsection (f) shall note the
22	discussion in the patient's medical record.
23	SECTION 2. The change in law made by this Act applies only
24	to a prescription issued on or after the effective date of this Act.

1

A prescription issued before the effective date of this Act is
governed by the law in effect on the date the prescription is
issued, and the former law is continued in effect for that purpose.
SECTION 3. This Act takes effect September 1, 2019.

H.B. No. 1710